We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Okyo Pharma Limited | LSE:OKYO | London | Ordinary Share | GG00BD3FV870 | ORD NPV |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 91.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.20 | 1.60 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 91.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/4/2024 | 00:00 | UKREG | OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to.. |
| 02/4/2024 | 12:00 | UKREG | OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry.. |
| 22/3/2024 | 11:00 | UKREG | OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance.. |
| 21/3/2024 | 11:00 | UKREG | OKYO Pharma to Host Key Opinion Leader Event to Discuss New and.. |
| 20/3/2024 | 11:00 | UKREG | OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye.. |
| 09/2/2024 | 12:36 | IHNW | OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal.. |
| 09/2/2024 | 12:00 | UKREG | OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal.. |
| 31/1/2024 | 12:00 | UKREG | OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the.. |
| 22/5/2023 | 08:15 | UKREG | OKYO Pharma Limited London Stock Exchange Delisting |
| 22/5/2023 | 08:00 | UKREG | London Stock Exchange Notice Cancellation - OKYO PHARMA LIMITED |
Okyo Pharma (OKYO) Share Charts1 Year Okyo Pharma Chart |
|
1 Month Okyo Pharma Chart |
Intraday Okyo Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/1/2024 | 13:18 | OKYO Pharma PLC | 693 |
| 17/4/2019 | 05:44 | (OKYO) OKYO Pharma Says Data Shows Potential Of Its Dry Eye Treatment | 6 |
| 17/4/2019 | 05:44 | OKYO PHARMA (OKYO) | 14 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 04/4/2023 21:19 by faraweigh2 On NASDAQ maybe tick thwat?NASDAQ will underpin Market Cap and OKYO will indeed go stratospheric. Hardly rocket science ffs.Doh |
Posted at 04/4/2023 15:31 by faraweigh2 lol!!Read the RNS detail as all is quite clear.Onwards and upwards is the way for the Market Cap here at Okyo. Fact. |
Posted at 04/4/2023 08:08 by babbler Not a surprise. UK investors don't get OKYO. |
Posted at 03/4/2023 13:37 by jimduggen They will have to take the share price up here soon. Nasdaq stock is going up 10% a day |
Posted at 01/4/2023 08:46 by faraweigh2 Just look at the 1 and 5 day OKYO trading summary charts on NASDAQ. Awesome! |
Posted at 18/3/2023 17:18 by spkp313703 Hi why is just a big price difference between Nasdaq and LSE share price 2.75 v/s 1.55? |
Posted at 16/3/2023 11:22 by bibs OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website."We are excited to be very close now to moving this drug into its first clinical trial and believe that OK-101 can provide a new way to treat DED patients who are presently not well-served by currently approved drugs" said Gary S. Jacob, Ph.D., CEO of OKYO Pharma Ltd. |
Posted at 13/3/2023 15:49 by bibs Okyo CEO states:"2023 is going to be a big year for us!"Shareholder value to be added here... |
Posted at 13/1/2023 11:23 by faraweigh2 Requoted in part from S/T:OKYO Pharma (OKYO): 2.75p Target 7p A problem with the bear market in small caps is that some timelines have been stretched, as well as valuations kept a lid on until companies are much further down the line as far as their milestones. A good example of both delayed market response and depressed share price is dry eye treatment group OKYO. Of course, it may be the case that even after the latest announcement of clearance of its Investigational New Drug (IND) application from the FDA to initiate a Phase 2 human clinical study. What the market has perhaps still not cottoned onto are a few factors here with OKYO. The dry eye treatment market is a multi-billion dollar one, with the jump in technology with OK-101 which is a treatment, rather than current applications which mere address the symptoms of dry eyes in a mechanical way. Just as important is that because OK-101 is a topical treatment it will have accelerated FDA approval, a point underlined by this month’s news from the company. Such an accelerated approved clearly means that the costs of development are that much more economic. Finally, given the way that the market cap is back to where it was two years ago, despite the advances made, we could see a realignment in 2023, especially given the drug will be “moving into the clinic in the first quarter of 2023"? |
Posted at 17/9/2020 15:55 by dodobird25 Thank you for your reply. I am in total agreement, and I too should have sold when the OKYO share price was listed at around 18p. This has proven to be the case with other pharmaceuticals recently (TILS, SNG to mention two).No more FOMO for me - I have proven it to be a loser's game in the main part. From now on, I shall be selling, when a healthy profit has been achieved, and perhaps buying back if there is a significant pullback. I wish you well with your future investments. Your prediction regarding OKYO, when at its recent peak, has been proven to be correct. We should have a clearer indication as to where this share price is heading next week. I see nothing untoward in my research, but several companies, whose retail shareholders were anticipating significant growth following results, have come unstuck recently. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
